AstraZeneca PLC Stock Forecast for 2022 - 2025 - 2030

Updated on 18.08.2022

Stock Rating
18
Price Target
£145,69
Consensus
Outperform
Upside
32,42%
Analysts
13
Stock Rating
18
Upside
32,42%
Analysts
13
Price Target
£145,69

AstraZeneca PLC has an average price target of £145,69 recently offered by thridteen notable experts for 2022, which would represent a potential upside of approximately 32,42% from the last closing price in August, 2022 if reached. This potential increase is based on a high estimate of £187,59 and a low estimate of £83,61. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.

£145,69

32,42% Upside

Outperform
Outperform

AstraZeneca PLC Fair Value Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Price has grown in the last three years, jumping from £59,51 to £90,99 – an increase of 52,89%. In the next year, analysts predict that Fair Value will reach £102,54 – an increase of 12,70%. For the next nine years, the forecast is for Fair Value to grow by 198,83%.

2022 Fair Value Forecast
£102,54
2023 Fair Value Forecast
£119,02
2024 Fair Value Forecast
£138,51
2025 Fair Value Forecast
£156,61
2026 Fair Value Forecast
£177,21
2027 Fair Value Forecast
£199,22
2028 Fair Value Forecast
£221,95
2029 Fair Value Forecast
£246,30
2030 Fair Value Forecast
£271,90
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
JNJ Stock Forecast Johnson & Johnson Outperform 12
$167,58 $186,00 10,40% 15
LLY Stock Forecast Eli Lilly and Outperform 16
$316,82 $281,95 8,89% 12
PFE Stock Forecast Pfizer Outperform 3
$49,27 $56,86 11,63% 16
ABBV Stock Forecast AbbVie Outperform 9
$141,44 $164,23 13,12% 19
NOVO B Stock Forecast Novo Nordisk A/S Outperform 18
kr773,00 kr678,96 15,14% 14

AstraZeneca PLC Revenue Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Revenue has grown in the last three years, jumping from £22,09B to £37,42B – an increase of 69,38%. In the next year, analysts predict that Revenue will reach £43,24B – an increase of 15,55%. For the next nine years, the forecast is for Revenue to grow by 235,44%.

2022 Rev Forecast
£43,24B
2023 Rev Forecast
£50,55B
2024 Rev Forecast
£60,11B
2025 Rev Forecast
£68,89B
2026 Rev Forecast
£78,80B
2027 Rev Forecast
£89,63B
2028 Rev Forecast
£100,80B
2029 Rev Forecast
£112,80B
2030 Rev Forecast
£125,51B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
MRK Stock Forecast Merck Outperform 6
$91,04 $91,73 9,84% 19
ABT Stock Forecast Abbott Laboratories Outperform 14
$110,55 $128,88 13,98% 19
NOVN Stock Forecast Novartis Outperform 18
CHF81,23 CHF103,75 17,79% 10

AstraZeneca PLC Dividend per Share Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's Dividend per Share has increased by 2,50%, going from £2,80 to £2,87. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach £2,89 – an increase of 0,81%. The AstraZeneca PLC forecast is for Dividend per Share to reach £3,18 or grow by 10,88%.

2022 DPS Forecast
£2,89
2023 DPS Forecast
£2,92
2024 DPS Forecast
£2,97
2025 DPS Forecast
£3,00
2026 DPS Forecast
£3,04
2027 DPS Forecast
£3,07
2028 DPS Forecast
£3,11
2029 DPS Forecast
£3,15
2030 DPS Forecast
£3,18
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$74,56 $79,05 11,32% 16
AMGN Stock Forecast Amgen Hold 9
$250,58 $246,51 1,76% 13
MDT Stock Forecast Medtronic Outperform 18
$94,91 $109,62 14,85% 5

AstraZeneca PLC Free Cash Flow Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Free Cash Flow has increased by 209,33% In the last three years, going from £1,58B to £4,87B. In the next year, analysts expect Free Cash Flow to reach £6,34B – an increase of 30,07%. For the next nine years, the forecast is for Free Cash Flow to grow by 449,31%.

2022 FCF Forecast
£6,34B
2023 FCF Forecast
£8,29B
2024 FCF Forecast
£10,17B
2025 FCF Forecast
£12,38B
2026 FCF Forecast
£14,84B
2027 FCF Forecast
£17,46B
2028 FCF Forecast
£20,34B
2029 FCF Forecast
£23,45B
2030 FCF Forecast
£26,76B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
CSL Stock Forecast CSL Outperform 16
$292,50 $228,01 -23,62% 6
GILD Stock Forecast Gilead Sciences Outperform 11
$66,02 $69,65 6,03% 19
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 18
182,90€ 147,51€ 12,08% 15

AstraZeneca PLC Net Income Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's Net Income has gone down from £2,16B to £112,00M – a 94,80% drop. For next year, the 0 analysts predict Net Income of £1,18B, which would mean an increase of 957,74%. Over the next nine years, the pros' prediction is Net Incomeof £1,89T, which would mean a nine-year growth forecast of 1690723,96%.

2022 NI Forecast
£1,18B
2023 NI Forecast
£12,65B
2024 NI Forecast
£136,35B
2025 NI Forecast
£259,94B
2026 NI Forecast
£458,27B
2027 NI Forecast
£735,60B
2028 NI Forecast
£1050,73B
2029 NI Forecast
£1439,40B
2030 NI Forecast
£1893,72B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BDX Stock Forecast Becton, Dickinson and Outperform 17
$264,23 $274,67 5,97% 3
GSK Stock Forecast GSK Outperform 16
£14,15 £16,08 37,10% 15
MRNA Stock Forecast Moderna Outperform 11
$158,00 $0,00 22,47% 3

AstraZeneca PLC EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's EBITDA has grown, increasing from £4,49B to £8,37B – a growth of 86,32%. The next year looks promising for AstraZeneca PLC, with analysts predicting EBITDA of £9,94B – an increase of 18,72%. Over the next nine years, experts anticipate that AstraZeneca PLC's EBITDA will grow at a rate of 233,63%.

2022 EBITDA Forecast
£9,94B
2023 EBITDA Forecast
£11,65B
2024 EBITDA Forecast
£13,57B
2025 EBITDA Forecast
£15,59B
2026 EBITDA Forecast
£17,77B
2027 EBITDA Forecast
£20,10B
2028 EBITDA Forecast
£22,56B
2029 EBITDA Forecast
£25,17B
2030 EBITDA Forecast
£27,93B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4,14k ¥0,00 3,99% 0
BAYN Stock Forecast Bayer Outperform 7
53,37€ 67,79€ 46,15% 14
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3,88k ¥0,00 16,01% 0

AstraZeneca PLC EBIT Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's EBIT has grown by 159,16%, from £1,76B to £4,57B. For the next year, analysts are expecting EBIT to reach £5,75B – an increase of 25,82%. Over the next nine years, experts predict that EBIT will grow by 259,37%.

2022 EBIT Forecast
£5,75B
2023 EBIT Forecast
£6,79B
2024 EBIT Forecast
£7,81B
2025 EBIT Forecast
£9,08B
2026 EBIT Forecast
£10,37B
2027 EBIT Forecast
£11,73B
2028 EBIT Forecast
£13,22B
2029 EBIT Forecast
£14,77B
2030 EBIT Forecast
£16,42B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
LONN Stock Forecast Lonza Group Ltd Outperform 16
CHF560,60 CHF756,46 40,47% 5
BAS Stock Forecast BASF Outperform 11
42,69€ 78,27€ 28,84% 16
BNTX Stock Forecast BioNTech Outperform 12
$152,04 $0,00 31,93% 5

AstraZeneca PLC EPS Price Prediction Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's EPS has grown in the last three years, jumping from £3,46 to £5,29 – an increase of 52,89%. In the next year, analysts predict that EPS will reach £5,96 – an increase of 12,70%. For the next nine years, the forecast is for EPS to grow by 198,83%.

2022 EPS Forecast
£5,96
2023 EPS Forecast
£6,92
2024 EPS Forecast
£8,05
2025 EPS Forecast
£9,11
2026 EPS Forecast
£10,30
2027 EPS Forecast
£11,58
2028 EPS Forecast
£12,90
2029 EPS Forecast
£14,32
2030 EPS Forecast
£15,81
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ILMN Stock Forecast Illumina Outperform 16
$213,02 $258,53 13,13% 11
BIIB Stock Forecast Biogen Outperform 11
$217,58 $242,78 5,71% 24
BAX Stock Forecast Baxter International Outperform 17
$61,38 $69,92 12,41% 3